Kornimate/medical-research-clean huggingface dataset:
evaluate the safety and therapeutic effects of transplantation of mnv-201 in pediatric patients with pearson syndrome

Conditions: Mitochondrial Diseases; Pearson Syndrome

Summary: primary mitochondrial diseases are a clinically and genetically heterogeneous group of disorders caused by mutations in genes encoded by nuclear deoxyribonucleic acid (dna) or by mutations and/or deletions in the mitochondrial dna (mtdna). while some mitochondrial disorders only affect a single organ (e.g., the eye in leber hereditary optic neuropathy \[lhon\]), many involve multiple organs. mitochondrial disorders may present at any age and a frequent feature is the increasing number of organs involved in the course of the disease. minovia therapeutics ltd. ("minovia") is a biotech company developing novel therapeutics based on its mitochondrial augmentation technology (mat). mnv-201 is a cell therapy produced by mat that consists of the participant's autologous cd34+ hematopoietic stem and progenitor cells (hspcs) enriched with allogeneic placental-derived mitochondria, manufactured in minovia's gmp facility.


Eligibility criteria:
inclusion criteria: 1. male or female participants aged from 1 to 18 years old. 2. diagnosis of pearson syndrome 3. body weight ≥ 10 kg. 4. participant has anemia and/or thrombocytopenia, and/or leukopenia and/or blood transfusion dependent (receives blood transfusions every 6 weeks or less). 5. participant is medically able to undergo the study interventions, as determined by the investigator. 6. participant's living parent(s) and/or legal guardian(s) able to understand and provide voluntary written informed consent. exclusion criteria: 1. history of infection with hiv-1, hiv-2, and htlv i/ii. 2. current active infection with hbv (including hbcore and hbsag positive), hcv, htlv i/ii, treponema pallidum and hiv i-ii 3. participant has been diagnosed with myelodysplastic syndrome, by fish and/or karyotype. 4. participant is unable to undergo leukapheresis. 5. total number of cd34+ cells collected is lower than 20x106 cells 6. participant has known hypersensitivity to murine proteins or iron-dextran. 7. participant has chronic severe infection. 8. participant has disease or condition that may risk the participant or interfere with the ability to interpret the study results. 9. history of malignancy 10. history of treatment with gene therapy, bone marrow or allogeneic cord blood transplantation. 11. currently participating in another clinical trial, or participation in another clinical trial within 1 year prior to study enrollment. 12. in the opinion of the investigator, the participant is unsuitable for participating in the study for any reason.

Keywords: autologous mitochondrial pearson transplantation stem cell
painful and barometric dynamic monitoring in the aftermath of foot surgery using the distal metatarsal mini-invasive osteotomy (dmmo) method

Conditions: Distal Metatarsal Mini-invasive Osteotomy (DMMO)

Summary: the definitive treatment of disabling metatarsalgia requires surgery. in recent years, a percutaneous technique has been developed, the "distal metatarsal mini-invasive osteotomy" (dmmo). it consists of performing extra-articular osteotomies that are not osteosynthesized and maintained during the time of bone consolidation by a dressing and specific offloading footwear.the patient is encouraged to resume walking immediately after the procedure, as full plantar support is an integral part of the surgical concept. the goal is to actively modify the distribution of all metatarsal supports by the pressure exerted on the ground during walking and by tendon tensions, in order to reduce forefoot deformities. dmmo offers many advantages over traditional techniques, but it remains a painful forefoot surgery in the short term despite the systematic use of analgesics and the wearing of a dedicated therapeutic shoe. the study will seek to identify the predictive character of podobarometric parameters at walking (d+7 and d+30 post-op), between patients who will require a palliative solution versus those who will not (d+90)


Eligibility criteria:
inclusion criteria: * adult person * affiliated or beneficiary of a statutory social insurance scheme * free ans informed consent * following foot surgery like dmmo only or dmmo and hallux valgus exclusion criteria: * minor or legally protect adult * amputation disturbing the natural course of the step * osteoarticular diseases/sequelae affecting walking and/or balance * neuromuscular diseases/sequelae affecting walking and/or balance * vestibular disorders affecting balance * patients requiring a walking aid (e.g., walker) * pregnant woman * patient with dementia who are unable to follow verbal instructions

Keywords: distal metatarsal mini-invasive osteotomy dmmo podobarometry
influence of diuresis timing (f+0 vs f-15) on 99m tc dtpa renography for the diagnosis of suspected obstructive uropathy

Conditions: Renal Scan in Suspected Obstructive Uropathy in Adult Hydronephrotic Patient

Summary: evaluation of the influence of the diuretic injection timing (f+0 vs f-15) on the dynamic 99mtc- dtpa renal scintigraphy for the diagnosis of suspected obstructive uropathy in adult hydronephrotic patients.

obstructive uropathy can be defined as any blockage of urine drainage from the kidney (renal calyces or renal pelvis), ureter, or bladder. as a result of the blockage, urine backs up into the kidneys, causing dilatation of the ureter, renal pelvis, and renal calyces, which can damage the kidney if it is not treated. the appearance of dilated or enlarged renal pelvis and calyces is referred to as hydronephrosis and is a symptom of obstructive uropathy. diuresis renography(renal scan with using of diuretic drug such as furosemide) is non-invasive test which is based on a high endogenous rate of urine flow stimulated by the administration of furosemide. interpretation of the test is based on the rate of washout of the radiopharmaceutical from the collecting system in the upper urinary tract. a number of different protocols exist in terms of the timing of furosemide injection, (f+0) protocol in which furosemide is injected at the same time of radiotracer administration \&( f - 15)protocol in which furosemide is administered 15 min before tracer administration.

Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years. * patients with hydronephrosis (unilateral or bilateral) referred for renal scan. * patients able to sleep in a fixed position for 20 minutes. exclusion criteria: * severely impaired renal function. * advanced hydronephrosis * pregnancy.
rct of continuous versus intermittent infusion of vancomycin in neonates

Conditions: Sepsis; Infection; Bacteremia

Summary: babies aged 0 to 90 days with a suspected infection requiring treatment with vancomycin will be recruited. they will be randomised to receive vancomycin as an intermittent infusion (over 1 hour) or as a continuous infusion (over 24 hours). the hypothesis is that administering vancomycin as a continuous infusion will result in improved attainment of target concentrations in blood at steady state (when the drug is in equilibrium) compared to intermittent infusion.


Eligibility criteria:
inclusion criteria: - neonates in the neonatal unit with an infection requiring treatment with vancomycin as determined by the treating physician. exclusion criteria: * infants with a corrected gestational age \< 25 weeks. * allergy to vancomycin or other glycopeptide antibiotic * vancomycin administered within the previous 72 hours * renal impairment * prior enrolment in the study * need for drug that is incompatible with vancomycin (if no other iv line is available)
indications for breast reduction in the public health care system

Conditions: Mammary Gland Hyperplasia

Summary: the overall purpose of the project is to create a scientific basis for which patients should be offered breast reduction in the public sector. more specifically , the project aims to: * to examine the evidence for current national guidelines for breast reduction. the hypothesis is that bmi, breast volume, resection weight, and mental and physical symptoms affect the outcome of breast reconstruction, both in terms of complication risks, patient satisfaction and quality of life . * to investigate which patients benefit the most from a breast reduction, in a health economic perspective. the starting point is that resources are limited and the purpose is to maximize the health effects for the patient at as low cost as possible. the hypothesis is that the health benefits, for the individual and society, are different depending on how big the breasts are and how much symptoms a patient has preoperatively. * to examine back function and objective problems in women, with both natural and augmented breasts, with different body constitutions and volumes. the hypothesis is that a certain breast volume give rise to different physical symptoms in different women, depending on their other physical factors. * to develop preferences for benign breast conditions that are treated in plastic surgery and for complications that the treatment can cause. preferences are used to calculate qaly (quality-adjusted life years). knowledge of preferences is essential for an analysis of healthcare needs. * to examine women's experiences of how their breast hypertrophy affects them and their expectations of a breast reduction. the hypothesis is that the experience breast hypertrophy affects patients differently, and that expectations on a breast reduction can vary between different individuals.


Eligibility criteria:
inclusion criteria: * breast volume \> 800 ml * bmi\< 25 if under 50 years of age and bmi\<2 if over the age of 50 * symptoms of breast hypertrophy * non-smokers un-operad controls: -symptoms of breast hypertrophy, but do not comply with the criteria above. augmented controls: * augmented breast volume \> 800 ml * bmi\< 25 if under 50 years of age and bmi\<2 if over the age of 50 exclusion criteria: * inability to provide informed consent * inability to understand the swedish language * age under 18 years

Keywords: breast reduction reduction mammaplasty breast hypertrophy
trial to compare ffr measurement with a non-side-hole guide catheter vs. a side-hole guide catheter

Conditions: Coronary Artery Disease

Summary: the investigators propose a single center prospective study that will assess two different strategies for measuring fractional flow reserve (ffr) in patients undergoing clinically-indicated coronary angiography in whom ffr measurement is indicated. ffr will be measured with a non-side hole guide catheter (with the guide catheter both engaged and disengaged from the coronary ostium) and with a side-hole guide catheter (with the guide catheter both engaged and disengaged from the coronary ostium) to determine, whether measurements obtained with an engaged side-hole guide catheter are more accurate as compared with those obtained with the engaged non-side hole catheter.


Eligibility criteria:
inclusion criteria: * undergoing a clinically indicated coronary catheterization * need ffr of a coronary artery lesion * agree to participate and able to provide informed consent exclusion criteria: * significant difficulty advancing the pressure measuring guidewire into the coronary artery * severe chronic obstructive pulmonary disease * severe ostial disease (\>70% diameter stenosis within 5 mm from the coronary artery ostium)
midazolam additive to local anesthetic in peribulbar block

Conditions: Postoperative Pain; Cataract; Local Anaesthetic Complication; Midazolam

Summary: regional eye blocks are usually preferred for ophthalmic procedures. peribulbar block (pbb) is a safe alternative for patients undergoing cataract surgery. many studies tried to solve this issue by means of prolonging the duration of action of the local anesthetics used. several drugs were tried as adjuncts to local anesthetics, and their effects have been studied. midazolam added to the list of adjuvant used in the subarachnoid or epidural block can produce analgesia, probably mediated by the benzodiazepine-gamma amino-butyric acid(gaba) receptor complex. the investigators hypothesized that the addition of midazolam to lidocaine will improve the quality of the peribulbar block; fasten the onset and prolonging its anesthetic and analgesic duration.


Eligibility criteria:
inclusion criteria: * 90 adult patients with asa physical status i to iii * aged 40-70 years * scheduled for elective extracapsular or phacoemulsification cataract surgery with peribulbar block * no history of allergy to local anesthetics * axial length less than 28 mm. exclusion criteria: * patient's refusal to share in the study * communication barrier (e.g. impaired hearing, disturbed conscious level, impaired mental status) * uncontrolled tremors * morbidly obese patients * allergy to lidocaine * coagulation abnormalities * glaucoma * recent surgical procedure on the same eye.

Keywords: peribubar block - midazolam
safety and efficiency of photodynamic therapy for blie duct carcinoma

Conditions: Cholangiocarcinoma

Summary: this research is a prospective randomized controlled trial.it aimed to determine longterm outcomes and factors associated with increased survival after photodynamic therapy (pdt) through t-tube compared with biliary drainage alone in patients presenting with unresectable bile duct cancer.


Eligibility criteria:
inclusion criteria: * 1.patients with bile duct cancer 2.patients are willing to join in this clinical trial. exclusion criteria: * 1.patients with bile duct carcinoma can not suffer pdt procedure. 2.allergy to photosensitizer

Keywords: bili duct neoplasms bile duct cancer photodynamic therapy biliary drainage
green light and transcranial direct current stimulation in migraine patients

Conditions: Migraine

Summary: there is a lack of evidence on the clinical outcome of green light exposure, as it is the emerging, novel proposal of treatment. there are a lot of researches present with small sample size which should be done on large population. in last conducted studies, session numbers of the applied modality are less. there is no comparison of tdcs with green light for migraine. the literature suggested the neuromodulation influenced by these interventions that may result in reduction of migraine.

migraine treatments encompass both medicinal options, such as acute and preventive medications, as well as a variety of non-pharmacological therapies. the range of acute medications that are available can be categorized into four different treatment approaches for treating mild to moderate-severity attacks, which involve the use of acetaminophen and/or nsaids. for patients experiencing severe attacks or those who do not respond to the initial strategy, a triptan-based strategy is recommended. according to the american academy of neurology (aan), there is strong supporting evidence for the effectiveness of several medications in preventing migraines, including metoprolol, timolol, propranolol, divalproex sodium, sodium valproate, and topiramate. there are some non-pharmacological approaches present like non-invasive and invasive neuromodulation. in non-invasive treatment, transcutaneous cranial nerve stimulation, vagus nerve stimulation, single-pulse transcranial magnetic stimulation (stms), transcranial direct current stimulation (tdcs), percutaneous mastoid stimulation and non-painful brachial electric stimulation are involved. in invasive neuromodulation, occipital nerve stimulation, sphenopalatine ganglion stimulation, and high cervical spine cord stimulation are involved.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria established by the international headache society, * patient must have had at least 5 headache attacks that lasted 4-72 hours (untreated or unsuccessfully treated) * headache must have had at least 2 of the following characteristic; unilateral location \& pulsating quality, * an average headache pain intensity of migraine episodes of ≥5 at numeric pain scale (nps) over the 10 weeks prior to enrolling in the study. exclusion criteria: * mental illness, * photophobic individual, * presence of shunt and/or implant at the cranial region, * brain tumors, * wound at skull

Keywords: migraine green light transcranial direct current stimulation
intestinal and nasal microbiota of patients with idiopathic parkinson's disease

Conditions: Parkinson's Disease

Summary: the cause of parkinson's disease (pd) is unknown and a reliable biomarker to identify pd patients as early as possible is urgently needed. nerve cells near the nose and in the gut become first affected in pd and patients frequently suffer from loss of smell and constipation. the nose and gut harbor very high amounts of bacteria that influence our body functions in many ways, even in the brain. the investigators are examining a possible role of bacteria of the nose and gut in the pathogenesis of pd. this may lead to a better understanding of what pd causes and may open new possibilities for diagnosis and treatment. the investigators will recruit 100 pd patients and 100 control subjects. the investigators will characterize all subjects carefully with respect to clinical symptoms. the investigators will collect bacterial samples from the nose, mouth and stool of these subjects. using modern genomic techniques the investigators will read out the genetic code of all bacteria contained in these samples and will be able to identify which species of bacteria are present in the samples. using complex cluster computing the investigators will compare the pattern of bacterial species between pd patients and controls and look for specific abnormalities in pd patients. if the investigators can detect specific differences of bacterial communities between pd patients and controls this may point to a role of bacteria as a cause of pd. since there are many ways to influence bacterial communities pharmacologically (antibiotics, probiotics) it will be possible to investigate whether these therapies could alleviate or even reverse pd symptoms. furthermore, the investigators would be able to use these differences as a biomarker which would enable us to develop a quick screening test for bacterial samples that may reveal whether a person has pd or not. by doing this study the investigators will learn whether bacteria play a role in the development of pd and whether the investigators can use them as a biomarker or therapeutic target. so hopefully the investigators will be able in the future to better understand what causes pd, how the investigators can diagnose it as early as possible and how to cure patients from pd.


Eligibility criteria:
inclusion criteria: * over 50 years of age exclusion criteria: * active smoking * relevant gastrointestinal or ent disease

Keywords: metagenomic analysis microbiota
a multicenter, randomized, placebo-controlled, double-blind study of sun13834 in adult subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of the study is to explore the efficacy and safety of sun13834 vs placebo in adult participants with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * male or female participants between 18 and 65 years of age. * a diagnosis of atopic dermatitis (ad), meeting the guidelines for diagnosis of atopic dermatitis criteria * at least 1 inflammatory lesion eczema area and severity index (easi) score ≥5 at screening and prior to randomization (as per amendment 2 and 3). under the original protocol and amendment 1, no minimum easi score was required. exclusion criteria: * taking systemic immunosuppressive drugs or biologicals (within 3 months), or systemic corticosteroids therapy (within 4 weeks)prior to screening(note: inhaled, intranasal or otic corticosteroids are allowed). * use of phototherapy or tanning beds within 6 weeks of screening * history of reactive airway disease (asthma) requiring hospitalization in an intensive care unit in the last 5 years. * presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the clinical investigator) that will interfere with the interpretation of data from this patient (eg, renal impairment with non-atopic pruritus).

Keywords: atopic dermatitis sun13834
impact of the type of reconstruction methods on diabetes following laparoscopic distal gastrectomy in patients with gastric cancer and type 2 diabetes

Conditions: Stomach Neoplasms; Diabetes Mellitus, Type 2

Summary: there is a rapidly growing interest in metabolic surgery for the treatment of type 2 diabetes. however, its efficacy in the non-morbidly population is not clear yet and the underlying mechanism remains elusive. meanwhile, the incidence of early gastric cancer (egc) in korea has gradually increased, the long-term quality of life of the patients with egc has become an important issue. since the reconstruction methods after gastric cancer surgery are similar to that of metabolic surgery, some surgeons have attempted to modify the reconstruction methods after standard radical gastrectomy to achieve better glycemic control in gastric cancer patients with type 2 diabetes. the present study aimed to investigate the changes in glucose metabolism and incretin hormone responses following different types of reconstruction after distal gastrectomy in non-morbidly obese gastric cancer patients with type 2 diabetes. this is a non-randomized, prospective, single-center, phase ii pilot study. patients diagnosed with stage i gastric cancer and type 2 diabetes are eligible for the present study. patients who will undergo laparoscopic distal gastrectomy for cancer located at the lower two-thirds of the stomach will only be included. the reconstruction method will be selected among conventional billroth i, long-limb billroth ii (with 100 cm-long biliopancreatic limb), or long-limb roux-en-y (with 100 cm-long roux limb) reconstruction methods according to the surgeon's preference as well as the size of the remnant stomach. all the patients are subjected to a 75g-oral glucose tolerance test (ogtt) preoperatively, and at 5 days, 3 months, 6 months postoperatively and serum glucose, as well as incretin hormones, will be serially measured.


Eligibility criteria:
inclusion criteria: * patients diagnosed with type 2 diabetes as well as pathologically proven gastric cancer of clinical stage i according to the ajcc 7th edition * those who are expected to undergo laparoscopic distal gastrectomy * body mass index \< 30 kg/m2 exclusion criteria: 1. baseline fasting c-peptide level \< 1.0 ng/dl (who had the possibility of type 1 diabetes) 2. previous radiotherapy or surgery at upper abdomen other than laparoscopic cholecystectomy 3. other malignancies in recent 5 years 4. vulnerable patients (pregnant women, those with cognitive impairment, etc) 5. ecog-ps ≥ 2 6. participating in other clinical trials within 6 months